Eikon Therapeutics, Inc. (EIKN) AI Stock Analysis
Eikon Therapeutics, Inc.
(NASDAQ:EIKN)
No summary available
Eikon Therapeutics, Inc. (EIKN) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $316.17M
- Dividend Yield
- ―
- Average Volume (3M)
- 579.25K
- Price to Earnings (P/E)
- -1.3
- Beta (1Y)
- 2.02
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 384
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Eikon Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significan...
Eikon Therapeutics, Inc. Risk Analysis
Eikon Therapeutics, Inc. disclosed 87 risk factors in its most recent earnings report. Eikon Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksEikon Therapeutics, Inc. Peers Comparison
Overall Rating
PRME51Neutral
DNA47Neutral
CCCC45Neutral
IMRX43Neutral
FHTX42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| PRME | 51Neutral | $901.44M | -4.04 | -188.27% | ― | -17.90% | 32.10% |
| DNA | 47Neutral | $784.51M | -2.37 | -60.21% | ― | -51.54% | 7.05% |
| CCCC | 45Neutral | $383.84M | -4.10 | -37.71% | ― | 2.33% | 36.86% |
| IMRX | 43Neutral | $243.51M | -3.27 | -33.91% | ― | ― | 42.34% |
| FHTX | 42Neutral | $124.71M | -1.92 | 72.64% | ― | 51.98% | 17.68% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| EIKN | Eikon Therapeutics, Inc. | 5.84 | -9.16 | -61.07% | |
| CCCC | C4 Therapeutics, Inc. | 2.95 | 0.61 | 26.07% | |
| FHTX | Foghorn Therapeutics, Inc. | 1.91 | -2.46 | -56.31% | |
| DNA | Ginkgo Bioworks Holdings, Inc. | 9.96 | 1.01 | 11.28% | |
| IMRX | Immuneering Corp. Class A | 3.37 | -3.52 | -51.09% | |
| PRME | Prime Medicine, Inc. | 4.45 | 0.64 | 16.80% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.